Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Intravenous Therapy in Patients With Prosthetic Joint Infections

Trial Profile

Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Intravenous Therapy in Patients With Prosthetic Joint Infections

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2016

At a glance

  • Drugs Fusidic acid (Primary) ; Antibacterials; Rifampicin
  • Indications Bone and joint infections; Staphylococcal infections
  • Focus Therapeutic Use
  • Sponsors Cempra Pharmaceuticals
  • Most Recent Events

    • 28 Sep 2016 Results of this trial, published in the Clinical Infectious Diseases journal.
    • 17 Apr 2015 According to a Cempra Pharmaceuticals media release, results from this trial will be presented at the 25th European Congress of Clinical Microbiology (ECCMID).
    • 09 Jun 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top